Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company has a collaboration with autonomous therapeutics, inc. to develop novel therapies targeting metastatic tumors. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc. more
Time Frame | INKT | Sector | S&P500 |
---|---|---|---|
1-Week Return | -28.74% | -3.39% | -3.47% |
1-Month Return | -33.35% | -3.25% | -0.29% |
3-Month Return | -37.41% | -11.61% | 4.5% |
6-Month Return | -47.19% | -5.89% | 6.91% |
1-Year Return | -54.59% | 2.65% | 23.79% |
3-Year Return | -89.57% | 0.56% | 28.43% |
5-Year Return | -96.14% | 34.63% | 83.64% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 689.63K | - | - | 2.70B | - | [{"date":"2019-12-31","value":0.03,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | - | 55.06K | 28.36B | 30.95B | 204.62K | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":91.63,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Gross Profit | 689.63K | (55.06K) | (28.36B) | (28.24B) | (204.62K) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-7.98,"profit":false},{"date":"2021-12-31","value":-4112169.64,"profit":false},{"date":"2022-12-31","value":-4095630.82,"profit":false},{"date":"2023-12-31","value":-29.67,"profit":false}] |
Gross Margin | 100.00% | - | - | (1044.26%) | - | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-1044.26,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 23.48M | 10.80M | 18.61M | 30.95M | 22.92M | [{"date":"2019-12-31","value":75.87,"profit":true},{"date":"2020-12-31","value":34.89,"profit":true},{"date":"2021-12-31","value":60.12,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":74.06,"profit":true}] |
Operating Income | (22.28M) | (14.64M) | (28.36M) | (30.95M) | (22.92M) | [{"date":"2019-12-31","value":-2228447800,"profit":false},{"date":"2020-12-31","value":-1463718600,"profit":false},{"date":"2021-12-31","value":-2835859100,"profit":false},{"date":"2022-12-31","value":-3094927800,"profit":false},{"date":"2023-12-31","value":-2292110500,"profit":false}] |
Total Non-Operating Income/Expense | (3.08M) | (4.04M) | (4.29M) | 3.21M | 1.02M | [{"date":"2019-12-31","value":-95.86,"profit":false},{"date":"2020-12-31","value":-125.88,"profit":false},{"date":"2021-12-31","value":-133.46,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":31.76,"profit":true}] |
Pre-Tax Income | (23.80M) | (16.24M) | (30.21M) | (27.99M) | (22.46M) | [{"date":"2019-12-31","value":-2380218200,"profit":false},{"date":"2020-12-31","value":-1623889800,"profit":false},{"date":"2021-12-31","value":-3021277000,"profit":false},{"date":"2022-12-31","value":-2799121200,"profit":false},{"date":"2023-12-31","value":-2245785900,"profit":false}] |
Income Taxes | 2.11M | (560.38K) | (7.10M) | (3.21M) | 3.00 | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-26.53,"profit":false},{"date":"2021-12-31","value":-336.1,"profit":false},{"date":"2022-12-31","value":-152.05,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | (25.91M) | (15.68M) | (23.11M) | (24.78M) | (22.46M) | [{"date":"2019-12-31","value":-2591428500,"profit":false},{"date":"2020-12-31","value":-1567851700,"profit":false},{"date":"2021-12-31","value":-2311400900,"profit":false},{"date":"2022-12-31","value":-2477982300,"profit":false},{"date":"2023-12-31","value":-2245786200,"profit":false}] |
Income From Continuous Operations | (23.80M) | (16.24M) | (30.21M) | (27.99M) | (24.77M) | [{"date":"2019-12-31","value":-2380218200,"profit":false},{"date":"2020-12-31","value":-1623889800,"profit":false},{"date":"2021-12-31","value":-3021277000,"profit":false},{"date":"2022-12-31","value":-2799121200,"profit":false},{"date":"2023-12-31","value":-2476900100,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (25.91M) | (15.68M) | (23.11M) | (24.78M) | (22.46M) | [{"date":"2019-12-31","value":-2591428500,"profit":false},{"date":"2020-12-31","value":-1567851700,"profit":false},{"date":"2021-12-31","value":-2311400900,"profit":false},{"date":"2022-12-31","value":-2477982300,"profit":false},{"date":"2023-12-31","value":-2245785900,"profit":false}] |
EPS (Diluted) | (0.18) | (0.70) | (1.19) | (0.83) | (0.66) | [{"date":"2019-12-31","value":-17.98,"profit":false},{"date":"2020-12-31","value":-70.44,"profit":false},{"date":"2021-12-31","value":-119.06,"profit":false},{"date":"2022-12-31","value":-83,"profit":false},{"date":"2023-12-31","value":-66,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
INKT | |
---|---|
Cash Ratio | 855.28 |
Current Ratio | 888.66 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
INKT | |
---|---|
ROA (LTM) | -97.25% |
ROE (LTM) | -1238.98% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
INKT | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 3.38 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -2.38 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
INKT | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 10.05 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Mink Therapeutics Inc (INKT) share price today is $0.512
Yes, Indians can buy shares of Mink Therapeutics Inc (INKT) on Vested. To buy Mink Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in INKT stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Mink Therapeutics Inc (INKT) via the Vested app. You can start investing in Mink Therapeutics Inc (INKT) with a minimum investment of $1.
You can invest in shares of Mink Therapeutics Inc (INKT) via Vested in three simple steps:
The 52-week high price of Mink Therapeutics Inc (INKT) is $1.9. The 52-week low price of Mink Therapeutics Inc (INKT) is $0.46.
The price-to-earnings (P/E) ratio of Mink Therapeutics Inc (INKT) is
The price-to-book (P/B) ratio of Mink Therapeutics Inc (INKT) is 10.05
The dividend yield of Mink Therapeutics Inc (INKT) is 0.00%
The market capitalization of Mink Therapeutics Inc (INKT) is $18.32M
The stock symbol (or ticker) of Mink Therapeutics Inc is INKT